Abstract
Background Existing studies on osteoradionecrosis of the jaw (ORNJ) have primarily used cross-sectional data, assessing risk factors at a single time point. Determining the time-to-event profile of ORNJ has important implications to monitor oral health in head and neck cancer (HNC) long-term survivors.
Methods Demographic, clinical and dosimetric data were retrospectively obtained for a clinical observational cohort of 1129 patients with HNC treated with radiotherapy (RT) at The University of Texas MD Anderson Cancer Center. ORNJ was diagnosed in 198 patients (18%). A multivariable logistic regression analysis with forward stepwise variable selection identified significant predictors for ORNJ. These predictors were then used to train a Weibull Accelerated Failure Time (AFT) model, which was externally validated using an independent cohort of 265 patients (92 ORNJ cases and 173 controls) treated at Guy’s and St. Thomas’ Hospitals.
Findings Our model identified that each unit increase in D25% is significantly associated with a 12% shorter time to ORNJ (Adjusted Time Ratio [ATR] 0·88, p<0·005); pre-RT dental extractions was associated to a 27% faster (ATR 0·73, p=0·13) onset of ORNJ; male patients experienced a 38% shorter time to ORNJ (ATR 0·62, p = 0·11). The model demonstrated strong internal calibration (integrated Brier score of 0·133, D-calibration p-value 0.998) and optimal discrimination at 72 months (Harrell’s C-index of 0·72). The model also showed good generalization to the independent cohort, despite a slight drop in performance.
Interpretation This study is the first to demonstrate a direct relationship between radiation dose and the time to ORNJ onset, providing a novel characterization of the impact of delivered dose not only on the probability of a late effect (ORNJ), but the conditional risk during survivorship.
Funding This work was supported by various funding sources including NIH, NIDCR, NCI, NAPT, NASA, BCM, Affirmed Pharma, CRUK, KWF Dutch Cancer Society, NWO ZonMw, and the Apache Corporation.
Competing Interest Statement
S.J.F. is a consultant at Boston Scientific and founder and member of the Scientific Advisory Committee (with patient/royalties) at C4 Imaging. J.P. COI disclosures: Nanobiotix; TAE Life Sciences Clinical Advisory Board 2020-2023. C.D.F. receives unrelated patent royalties from Kallisio, Inc, and unrelated travel and honoraria from Elekta AB, Philips Medical Systems, Siemens Healthineers/Varian, and Corewell Health. C.D.F. holds patents through the University of Texas (US PTO 11730561) licensed to Kallisio, Inc. V.C.S. is a consultant for, and equity holder in Femtovox Inc and a consultant for PDS Biotechnology. K.A.W. serves as an Editorial Board Member for Physics and Imaging in Radiation Oncology. C.D.F. has served on guidelines/scientific committee for Osteoradionecrosis for the American Society of Clinical Oncology.
Funding Statement
The authors would like to acknowledge the support from various funding sources that made this work possible. C.D.F. and S.Y.L. received related funding support from the NIH/NIDCR (U01DE032168/ R01DE025248). C.D.F. also receives infrastructure and salary support through the NIH/NCI MD Anderson Cancer Center Core Support Grant (CCSG) Image-Driven Biologically-informed Therapy (IDBT) program (P30CA016672-47). S.Y.L. is supported through the CCSG Head and Neck Program (P30CA016672-48). T.G.U. is supported by the Radiation Research Unit at the Cancer Research UK City of London Centre Award [C7893/A28990]. A.C.M. received funding from the NIH/NIDCR via grants K12CA088084, R21DE031082, and K01DE030524. L.V.V. received funding and salary support from KWF Dutch Cancer Society through a Young Investigator Grant (KWF-13529) and from NWO ZonMw through the VENI grant (NWO-09150162010173). K.K.B. acknowledges support from the Image Guided Cancer Therapy Research Program at The University of Texas MD Anderson Cancer Center, which was partially funded by the National Institutes of Health/NCI under award number P30CA016672 and through a generous gift from the Apache Corporation. M.A.N. received funding from the National Institutes of Health/National Institute of Dental and Craniofacial Research (NIH/NIDCR) through grant 1R03DE033550-01. J.R. received salary support from the NIDCR Diversity Supplement Grant 3R01DE028290-02S1. K.A.W. was supported by the Image-Guided Cancer Therapy T32 Training Program Fellowship from T32CA261856. A.J.S. received funding from the NIH/NCI through grant R01CA257814-01. N.A.W. acknowledges funding support from 5R01DE028290-05. G.E.M. acknowledges funding support from NIH UG3 TR004501, NSF CNS-2320261, the University Scholar Award from the University of Illinois System, and NIH/NCI R01CA258827. A.S.R.M. received funding from NIDCR (U01DE032168, 1R01DE028290-01A1) and NCI (R01 CA258827). S.J.F. received funding from Hitachi, NIH/NCI, the National Association of Proton Therapy, Affirmed Pharma and NASA/Baylor College of Medicine and honoraria from IBA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
After institutional review board approval (RCR030800), data from a philanthropically funded observational cohort at The University of Texas MD Anderson Cancer Center (Stiefel Oropharynx Cancer Cohort, PA14-0947) were extracted for retrospective acquisition. An external cohort was obtained retrospectively from the HNC clinical database maintained at GSTT under the Northwest - Haydock Research Ethics Committee of the NHS Health Research Authority (REC reference 18/NW/0297, IRAS project ID: 231443)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* co-first authors
Data availability statement
The MDACC deidentified dataset is available in Figshare (10.6084/m9.figshare.26240435). The GSTT dataset was analyzed onsite using a federated method and, due to GDPR restrictions, cannot be made public. Open access/FAIR reporting of scripts and instructions for the model are available in GitHub (https://github.com/LaiaHV-MDACC/ORN-time-to-event-prediction-modelling).
